Ascentage Pharma Group International（AAPG）の株式分析AAPGAscentage Pharma Group International

Ascentage Pharma Group International is an investment holding company primarily engaged in the discovery, development, and commercialization of therapies for hematologic malignancies. The Company's main products include Olverembatinib (HQP1351), Lisaftoclax (APG-2575), Alrizomadlin (APG-115), Pelcitoclax (APG-1252), APG-5918, and APG-2449. The Company's products are primarily used to treat chronic myeloid leukemia (CML), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), acute lymphoblastic leukemia (ALL), myelodysplastic syndrome (MDS) and multiple myeloma (MM). The Company primarily conducts its businesses in domestic market. It operates in the Healthcare sector.

Ascentage Pharma (AAPG) is currently not a strong buy due to its recent performance and mixed analyst ratings. The stock is trading at $14.75, significantly down 44.07% year-to-date and 59.53% over the past year. The RSI is at 42.26, indicating it is near oversold territory, which could suggest a potential rebound. However, the forward P/E ratio is at 10.06, which is relatively low, suggesting the stock may be undervalued. The main risk is the significant revenue decline of 38.9% year-over-year, which raises concerns about the company's growth prospects.